Audrey Glover

Audrey Gover serves as a key procurement professional within the ASPR BARDA Division Contracts Management & Acquisition, supporting the Department of Health and Human Services’ mission to accelerate the development and scalable production of medical countermeasures against biological, chemical, radiological, and nuclear threats. In this role, she manages the full lifecycle of research and development contracts, focusing on advanced biomedical innovation to enhance national preparedness. Her acquisitions primarily involve early-stage R&D, preclinical validation, and process development for vaccines, therapeutics, and diagnostics, ensuring rapid transition from lab to large-scale manufacturing capability. She operates within a high-stakes, time-sensitive environment where regulatory compliance and technical feasibility are paramount. While specific contractor names are not publicly available, Audrey collaborates with a diverse ecosystem of biotechnology firms, contract research organizations, and specialized manufacturing entities capable of meeting stringent FDA and BARDA standards. Her working relationships emphasize technical rigor, agile contract execution, and performance-based outcomes, often involving cost-reimbursement and milestone-driven structures to mitigate risk in high-uncertainty R&D environments. She engages with both established biopharmaceutical leaders and emerging innovators with proven platform technologies in protein engineering, mRNA delivery, and rapid diagnostics. Audrey’s contracting portfolio reflects a strict preference for unrestricted competition, with 100% of awards issued under the “No Set-Aside” category. This indicates a focus on technical capability over socioeconomic classifications, prioritizing speed, scalability, and readiness over traditional small business set-asides. While she does not routinely utilize 8(a), HUBZone, or SDVOSB programs, her approach ensures that the most technically qualified entities—regardless of size or certification—are selected to meet urgent public health imperatives. Her primary procurement focus is centered on NAICS 541714, Research and Development in Biotechnology, encompassing novel platform development, biosafety level 3/4 pathogen handling, and GMP-scale process optimization. She routinely procures services related to antigen design, animal model validation, analytical method development, and supply chain resilience for medical countermeasures, demonstrating deep expertise in the biotech R&D lifecycle and federal biomedical acquisition policy.